AbbVie Secures FDA Approval for Juvmo, First D1/D5 Agonist for Parkinson's

Key points

• The FDA approved tavapadon (Juvmo) as the first selective D1/D5 receptor agonist for Parkinson's disease in the U.S.
• AbbVie will list Juvmo at $4,900 per 30-day supply, totaling $58,800 annually, according to William Blair.
• The approval is based on three successful Phase 3 trials (TEMPO-1, -2, and -3) that demonstrated improved motor function and 'on' time.
• Juvmo is expected to be available in the U.S. market next month, following its September 2025 new drug application filing.
• AbbVie's Chief Commercial Officer Jeffrey Stewart noted the drug targets a $5 billion market opportunity with a unique mechanism of action.

Background

AbbVie acquired Cerevel Therapeutics in late 2023 for $8.7 billion, with the deal closing in August 2024. The acquisition was primarily driven by the potential of emraclidine, a schizophrenia treatment, which suffered a significant Phase 2 failure in November 2024, causing AbbVie's shares to drop 12%. This setback placed increased pressure on other Cerevel assets, including tavapadon, to succeed. The approval of Juvmo follows a period of pipeline setbacks in the broader Parkinson's field, including failures by BioVie and Biogen/Denali in 2026.

How outlets are covering it

Fierce Pharma emphasizes the scientific novelty of Juvmo, highlighting its selective partial agonism on D1/D5 receptors as a solution to the side effects and motor fluctuations associated with traditional levodopa therapy. BioSpace focuses on the financial and strategic implications, noting that Juvmo's approval diversifies AbbVie's revenue base after the failure of the high-profile emraclidine asset. Yahoo Finance, while its content was largely obscured by technical errors, indicated that AbbVie management expects a slow commercial start for the drug despite the approval. Analysts from BMO Capital Markets and Jefferies view the approval as a positive diversification move for AbbVie's neuroscience portfolio, though they acknowledge the historical difficulty in developing effective Parkinson's therapies.

Why it matters

Juvmo represents the first dopaminergic breakthrough for Parkinson's treatment in decades, offering patients an alternative to levodopa that may reduce side effects like compulsive behaviors and insomnia. For AbbVie, it validates the $8.7 billion Cerevel acquisition after the failure of its primary target, emraclidine, and provides a new growth driver in the neuroscience sector. The drug's unique mechanism of action could shift treatment paradigms by allowing physicians to manage motor symptoms without the trade-offs associated with D2/D3 agonists.

What to watch

AbbVie expects to make Juvmo available in the U.S. market next month. The company will likely monitor early adoption rates and physician feedback, given management's expectation of a slow start. Investors will watch how Juvmo's commercial performance offsets the losses from the failed emraclidine program and contributes to AbbVie's overall revenue diversification.